EGFR and Skin rash: Among patients with wild-type EGFR who were assigned erlotinib and developed rash (n=94), HR for overall survival was 0·86 (95% CI 0·66–1·12, p=0·27) and for progression-free survival was 0·69 (0·53–0·90, p=0·0070; appendix p 2).